A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial-Reference-Cited by-同舟云学术

A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial

Published:2022-07 Issue: Volume:169 Page:77-83
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Banna Giuseppe Luigi,Addeo Alfredo,Zygoura Panagiota,Tsourti Zoi,Popat Sanjay,Curioni-Fontecedro Alessandra,Nadal Ernest,Shah Riyaz,Pope Anthony,Fisher Patricia,Spicer James,Roy Amy,Gilligan David,Gautschi Oliver,Janthur Wolf-Dieter,López-Castro Rafael,Roschitzki-Voser Heidi,Dafni Urania,Peters Solange,Stahel Rolf A.

Funder

MSD UK

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial;Pinto;Lancet Oncol.,2021

2. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial;Maio;Lancet Oncol.,2017

3. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial;Fennell;Lancet Oncol.,2021

4. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9–15) PROMISE-meso trial;Popat;Ann. Oncol.,2020

5. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial;Baas;Lancet,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Immunotherapy: A Promising New Standard of Care;International Journal of Molecular Sciences;2023-07-24